

IPHA welcomes the work of the National Clinical Trials Oversight Group, and urges this work to continue so that patients in Ireland can be included in life changing clinical trials.



Between 2023 and 2024, Ireland started* 75 pharmaceutical industry sponsored clinical trials compared to Denmark which started 229⁽³⁾.


*The clinical trial start date on CTIS refers to the date when recruitment for the clinical trial is opened in the Member State concerned.

For pharmaceutical industry sponsored clinical trials that began in both countries (n=42) between 2022 & 2024, Irish planned patient numbers were 362 compared to Denmark, with 609 planned to have access⁽³⁾.



For pharmaceutical industry sponsored clinical trials with an Irish start date of either 2023 or 2024, there were 773 patients expecting to access one of the 75 clinical trials⁽³⁾.

*The average time to first patient in** reduced by 31% in 2024 (46 days) compared to 2023 (67 days)⁽³⁾.*




**Time to first patient in₁ is from clinical trial start date to recruitment start date

***IRELAND CAN HAVE A LEAD ROLE
FOR CLINICAL TRIALS IN EUROPE.***

We have a strong base of international biopharmaceutical companies, alongside global clinical leaders, and a willing and adaptive policymaker community.

However, Ireland lags behind 17 of 27 European countries, ranking 18th, in relation to the number of pharmaceutical industry sponsored clinical trials being conducted per capita (100,000), based on 2024 data⁽³⁾.



Ireland is a hub for biological medicines manufacturing. We can be a leader in clinical research, too. Let's all work together for patients.